What this means
This is a trial plan that has not started yet, so no results exist. It will test whether the treatment may improve wrinkles, spots, and pores, but it cannot yet show that it works.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 18–65 · 40 adult participants
- Where
- Not listed
The science
- Registered title
- Objective Evaluation of Intradermal MSC-Derived Exosome Therapy on Facial Skin Quality
- Trial ID
- NCT07466953 ↗
- Phase
- PHASE 3
- Study type
- interventional
- Conditions
- Skin Aging, Facial Aging, Skin Quality
- What is tested
- Mesenchymal Stem Cell-Derived Exosome
- Sponsor
- Mert Ersan
- Ages
- 18 Years to 65 Years
- Dates
- First posted Mar 12, 2026 · updated Aug 7, 2026
Registry summary
This study aims to evaluate the potential effects of mesenchymal stem cell-derived suspended exosome therapy on facial skin quality using objective imaging analysis. Forty adult participants will receive intradermal exosome applications in three treatment sessions performed at one-month intervals. Facial skin analysis will be conducted using the VISIA imaging system before each treatment session and six months after the final treatment. The study will examine changes in multiple facial skin characteristics including wrinkles, pigmentation, skin texture, pores, UV spots, red areas, brown spots, and porphyrins to determine whether exosome therapy may improve overall facial skin quality.